阿斯卡里斯隆布里科伊德 (Ascaris Lumbricoides Cystatin) 损害了人类单细胞中的IL-1β成熟和CD14表达
Ana Lozano1, Josefina Zakzuk1, Nathalie Acevedo1
1Institute for Immunological Research, University of Cartagena, Cartagena, Colombia.
Immunology
|July 8, 2025
概括
阿斯卡里斯 (Ascaris lumbricoides) 囊素 (Al-CPI) 通过调节人类单细胞反应来降低炎症. 这种来自虫的蛋白质抑制了INTERLEUKIN-1β (IL-1β) 的成熟和释放,提供了潜在的治疗益处.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 寄生虫学的寄生虫学
背景情况:
- 阿斯卡里斯 lumbricoides 囊素 (Al-CPI) 具有抗炎性质.
- 单细胞是调节免疫力的囊类药物和虫产物的主要点.
- 虫衍生产品可以诱导免疫调节单细胞,减轻炎症和自身免疫性疾病.
研究的目的:
- 研究Al-CPI对人类单细胞的免疫调节作用.
- 阐明Al-CPI对单细胞作用的潜在机制.
主要方法:
- 在激活脂多糖 (LPS) 之前,将人体单细胞分离并用重组Al-CPI (rAl-CPI) 进行治疗.
- 流细胞计分析了表面标记物和caspase-1活动.
- 量化了细胞因子水平,酶-8抑制,亲IL-1β表达和基因表达 (RNA-seq).
主要成果:
- rAl-CPI降低了HLA-DR和CD14的细胞表面表达.
- 超级生物中的IL-1β水平降低,而亲IL-1β水平没有变化.
- rAl-CPI抑制了酶-1激活和调节基因表达,包括降低CD14和SLAMF1的调节,影响LPS介导的信号传递.
- 基因组丰富分析 (GSEA) 揭示了IFN信号通路的丰富.
结论:
- rAl-CPI通过调节替代性炎症酶激活来损害IL-1β的成熟和释放.
- 降低CD14和其他调节分子的调节可能会调节Al-CPI的影响.
- 通过调节单细胞功能,Al-CPI显示出作为治疗炎症状况的治疗剂的潜力.
相关概念视频
Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
Inflammatory Bowel Disease III: Crohn's Disease
35
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35


